Insulet Corp (PODD) 34.56 $PODD
Upgrade Alert for Insulet (PODD)
Comtex SmarTrend(R) - Fri May 09, 7:01AM CDT
Insulet (NASDAQ
ODD) was upgraded from Sell to Hold at Feltl today. The stock closed yesterday at $31.69 on volume of 2.1 million shares, above average daily volume of 689,000. In the past 52 weeks, shares of Insulet have traded between a low of $24.70 and a high of $51.31 and closed yesterday at $31.69, which is 28% above that low price. The 200-day and 50-day moving averages have moved 0.16% higher and 1.79% lower over the past week, respectively.
Insulet Down 32.5% Since SmarTrend Downtrend Call (PODD)
Comtex SmarTrend(R) - Thu May 08, 5:05PM CDT
SmarTrend identified a Downtrend for Insulet (NASDAQ ODD) on March 31st, 2014 at $46.97. In approximately 1 month, Insulet has returned 32.53% as of today's recent price of $31.69.
Insulet Reports First Quarter 2014 Results
Marketwire - Wed May 07, 3:16PM CDT
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced financial results for the first quarter ended March 31, 2014.
Insulet Corporation to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
Marketwire - Wed May 07, 5:02AM CDT
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced the Company will participate in the Bank of America Merrill Lynch 2014 Health Care Conference taking place at the Wynn Hotel in Las Vegas, Nevada. Management is scheduled to present an overview of the Company on Thursday, May 15, 2014 at 10:40 a.m. PT (1:40 p.m. ET).
19.3% Return Seen to Date on SmarTrend Insulet Call (PODD)
Comtex SmarTrend(R) - Thu May 01, 11:13AM CDT
SmarTrend identified a Downtrend for Insulet (NASDAQ ODD) on March 31st, 2014 at $46.97. In approximately 1 month, Insulet has returned 19.31% as of today's recent price of $37.90.
Insulet Corporation to Report First Quarter 2014 Financial Results on May 7, 2014
Marketwire - Tue Apr 29, 3:15PM CDT
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, announced plans to release its financial results for the first quarter of 2014 on May 7, 2014 after the close of the financial markets.
Xeris Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 2 Clinical Trial of its Investigational Soluble Glucagon Formulation for Pumps
GlobeNewswire - Thu Apr 24, 11:20AM CDT
Xeris Pharmaceuticals, Inc. ("Xeris"
, a clinical stage, specialty biopharmaceutical company developing novel, non-aqueous formulations of injectable drugs, announced today the dosing of the first subject in a Phase 2 clinical study of the company's stable liquid glucagon in an Insulet Corporation OmniPod infusion pump in patients with type 1 diabetes under a new US Investigational New Drug (IND) application. Xeris' G-Pump(TM) (glucagon infusion), a room-temperature stable glucagon solution, is a potentially effective and convenient treatment for hypoglycemia or low blood sugar. Currently, no commercial glucagon product is approved for use in any infusion pump. Glucagon is only approved and available in emergency kits (GEKs) marketed by Eli Lilly and Company and Novo Nordisk for the treatment of severe hypoglycemia. However, with these products, glucagon is available only as a dry powder in a sealed vial that must be reconstituted using a water-filled syringe in a multi-step process prior to injection. Xeris' glucagon formulation is a stable, ready-to-inject liquid which can be packaged and delivered with a variety of devices including auto-injectors, multi-dose pens and pumps.
Downtrend Call Working As Insulet Stock Falls 12.3% (PODD)
Comtex SmarTrend(R) - Thu Apr 24, 10:05AM CDT
SmarTrend identified a Downtrend for Insulet (NASDAQ ODD) on March 31st, 2014 at $46.97. In approximately 3 weeks, Insulet has returned 12.31% as of today's recent price of $41.19.
Equities to Watch in the Health Care Sector -- Research on Boston Scientific, Abbott Laboratories, Medtronic, and Insulet
PR Newswire - Thu Apr 24, 7:33AM CDT
The trading session on Wednesday, April 23, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,501.65, down 0.08% and the NASDAQ Composite closed at 4,126.97, down 0.83%. The S&P 500 finished the session 0.22% lower at 1,875.39. During the session, Telecommunication Services, Information Technology, and Health Care sectors exerted a drag, while some positive momentum was observed in the Energy, Industrials, and Financials sectors. The S&P 500 Health Care Sector Index edged 0.48% lower to finish the day at 670.12, while it has gained 1.59% in the last three months. Investor-Edge has initiated coverage on the following equities: Boston Scientific Corp. (NYSE: BSX), Abbott Laboratories (NYSE: ABT), Medtronic Inc. (NYSE: MDT) and Insulet Corp. (NASDAQ: PODD). Free technical research on BSX, ABT, MDT and PODD can be downloaded upon signing up at:
Shares of PODD Down 9.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Apr 16, 9:32AM CDT
SmarTrend identified a Downtrend for Insulet (NASDAQ ODD) on March 31st, 2014 at $46.97. In approximately 2 weeks, Insulet has returned 9.41% as of today's recent price of $42.55.
The US Diabetic Devices Industry Outlook to 2018 - Growth to be Led by Next Generation Technology
M2 - Mon Apr 07, 11:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3z9ktc/the_us_diabetic) has announced the addition of the "The US Diabetic Devices Industry Outlook to 2018 - Growth to be Led by Next Generation Technology" report to their offering. The report titled The US Diabetic Devices Industry Outlook to 2018- Growth to be Led by Next Generation Technology presents a comprehensive analysis of the industry covering aspects including market size of SMBG devices, CGM systems and Insulin Delivery Devices market by revenue and market segmentation by product categories in SMBG devices and Insulin Delivery Devices market. The report also entails a detailed description on the recent trends and developments in the diabetic care devices market and competitive scenario of major players in the industry along with market share of major companies in SMBG devices and Insulin Delivery devices market. Key Topics Covered: 1. The US Diabetes Care Devices Market Introduction 1.1. What is Diabetes and it's Types? 2. The US Diabetes Care Devices Market Size, 2007-2013 3. The US Diabetes Care Devices Market Segmentation, 2007-2013 3.1. By Blood Sugar Monitoring Devices, CGM Devices and Insulin Delivery Devices, 2010-2013 3.2. The US Self Blood Glucose Monitoring Devices Market Introduction 3.3. The US CGM Systems Market Introduction 3.4. The US Insulin Delivery Devices Market Size and Introduction, 2007-2013 3.5. Cause & Effect Relationship Analysis in the US Diabetic Care Devices Industry 4. Artificial Pancreas - The Ultimate Goal 5. Trends and Developments in the US Diabetic Care Devices Market 6. Prevalence of Diabetes across the US States 7. Patents Scenario in the US Diabetic Therapeutic Market 8. Strategic Partnerships and Acquisitions in the US Diabetic Market 9. The US Diabetic Care Devices Market SWOT Analysis 10. Company Profiles of Major Players in the US Diabetic Care Devices Market 11. The US Diabetic Care Devices Market Future Outlook and Projections, 2014-2018 12. The US Macro Economic Indicators: Current and Projections 12.1. Ageing Population in the US, 2007-2018 12.2. Consumer Healthcare Expenditure, 2007-2018 12.3. Diabetic Population in the US, 2007-2018 13. Appendix Companies Mentioned - Abbot laboratories - Dexcom inc - Insulet Corporation - LifeScan Inc - Medtronics - Novo Nordisk - Roche Diagnostics For more information visit http://www.researchandmarkets.com/research/3z...s_diabetic
Shares of PODD Up 33.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Mar 26, 4:43PM CDT
SmarTrend identified an Uptrend for Insulet (NASDAQ ODD) on November 29th, 2013 at $36.86. In approximately 4 months, Insulet has returned 33.32% as of today's recent price of $49.14.
Sean Busby Becomes First Person With Type 1 Diabetes to Successfully Backcountry Snowboard All Seven Continents
Marketwire - Thu Mar 20, 9:36AM CDT
Riding On Insulin, a nonprofit organization that empowers, activates and connects the global diabetes community through shared experience and action sports, and Insulet (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, are proud to announce that professional snowboarder Sean Busby has become the first person with type 1 diabetes (T1D) to successfully backcountry snowboard on each of the seven continents. Sean, an OmniPod ambassador and the founder of Riding On Insulin, began his seven-continent mission in 2008, just four years after he was diagnosed with type 1 diabetes while training for the 2010 Olympics. From Antarctica in 2008 to Africa in 2014, Sean explored remote corners of the globe while proving that T1D can't stop people from reaching the highest peaks in life.
Increased Earnings Estimates Seen for Insulet (PODD): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:31AM CDT
Insulet has decent short-term momentum and is seeing solid activity on the earnings estimate revision front. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Insulet could be a solid choice for investors.
Concise Analysis of the International Insulin Pump Market
M2 - Tue Mar 18, 5:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wwx6kq/insulin_pump) has announced the addition of the "Concise Analysis of the International Insulin Pump Market" report to their offering. Insulin Pumps are gaining strong acceptance in the market as insulin delivery systems especially for type 1 diabetes patients. Insulin pumps are gaining a lot of attraction in United States and European countries. But due to high costs of insulin pumps it has still not able to penetrate successfully in emerging markets. If insulin pump cost declines then its market is expected to grow immensely. Number of insulin pump users is expected to grow with single digit CAGR for the period of 2013 to 2018. For the year 2013 United States is having the highest market share in insulin pump market worldwide. In terms of companies share Medtronic controls a major portion of insulin pump market globally. Insulin pump market is more than 4 Billion for the year 2013. Reimbursement plays an important factor for the growth of insulin pump in any country. 1. Overall Diabetes Population (2007 - 2018) 2. Type 1 Diabetes Population (2007 - 2018) 3. Type 2 Diabetes Population (2007 - 2018) 4. Insulin Pump Users (2007 - 2018) 5. Insulin Pump Market (2007 - 2018) 6. Reimbursement Policies of all the 16 Countries Key Topics Covered: 1. Executive Summary 2. Worldwide - Insulin Pump Users & Forecast 3. Worldwide - Insulin Pump Market & Forecast 4. Worldwide - Insulin Pump Market Share & Forecast 5. United States - Insulin Pump Analysis 6. Canada - Insulin Pump Analysis 7. Japan - Insulin Pump Analysis 8. Germany - Insulin Pump Analysis 9. Norway - Insulin Pump Analysis 10. Australia - Insulin Pump Analysis 11. Italy - Insulin Pump Analysis 12. Spain - Insulin Pump Analysis 13. France - Insulin Pump Analysis 14. Netherlands - Insulin Pump Analysis 15. Switzerland - Insulin Pump Analysis 16. Sweden - Insulin Pump Analysis 17. Israel - Insulin Pump Analysis 18. United Kingdom - Insulin Pump Analysis 19. Denmark - Insulin Pump Analysis 20. Finland - Insulin Pump Analysis 21. Worldwide Insulin Pump - Key Players Analysis 22. Growth Drivers 23. Challenges Companies Mentioned: - Animas Corporation (Acquired by Johnson & Johnson) - Insulet Corporation - Medtronic - Roche For more information visit http://www.researchandmarkets.com/research/ww...sulin_pump
Uptrend Call Working As Insulet Stock Rises 30.5% (PODD)
Comtex SmarTrend(R) - Wed Mar 12, 9:36AM CDT
SmarTrend identified an Uptrend for Insulet (NASDAQ ODD) on November 29th, 2013 at $36.86. In approximately 3 months, Insulet has returned 30.55% as of today's recent price of $48.12.
Upcoming Conferences, Financial Results, New Products, and Awareness Campaigns - Analyst Notes on Align Technology, LabCorp, Insulet, CareFusion, and DexCom
PR Newswire - Tue Mar 11, 8:20AM CDT
Today, Analysts Review released its analysts' notes regarding Align Technology, Inc. (NASDAQ:ALGN), Laboratory Corp. of America Holdings (NYSE:LH), Insulet Corporation (NASDAQ ODD), CareFusion Corporation (NYSE:CFN), and DexCom, Inc. (NASDAQ
XCM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Earnings Estimates Moving Higher for Insulet (PODD): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 7:47AM CST
Insulet has decent short-term momentum plus a solid activity on the earnings estimate revision front as well
Global Continuous Glucose Monitoring (CGM Systems, Application, Diabetic Type, and Adoption by Age Group) Market to 2020
M2 - Thu Mar 06, 11:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/k2xw8h/continuous) has announced the addition of the "Continuous Glucose Monitoring Market (CGM Systems, Application, Diabetic Type, and Adoption by Age Group) - Current Trends, Size, Share, Industry Analysis, Competitive Intelligence, Growth, Opportunities and Global Forecasts, 2012 - 2020" report to their offering. The global continuous glucose monitors market generated revenue of $194.8 million in 2012 and is expected to reach market size of value $568.5 million by 2020, growing at a CAGR of 14.8% during 2013-2020. This growth is attributed to increase in technological innovations, namely launch of artificial pancreas, convenience offered by CGM over self monitoring glucose devices, and earlier detection of the hypo & hyperglycemic events by CGM. Global CGM market is segmented based on application as home settings, diagnostics and hospitals. Among all the application segments home settings is expected to generate maximum revenue by 2020. North America is the maximum revenue-generating segment across the globe, mainly due to rapid acceptance of innovative technology, well-penetrated reimbursement system when compared with other geographies and rise in patient pool. Asia Pacific is expected to grow at a faster rate due to large patient pool, geographical expansion of market players, increase in income levels and improved living standards of the people. Key market players in this market includes, Medtronics, Dexcom, Animas Corporation, Ypsomed AG, Omnipod and Miraculins, Inc inlcuding others. The major strategy adopted the market players across this geography is Collaborations, Product launches and approvals. Collaborations specifically focus on distribution and commercialization of the devices. KEY BENEFITS - The report ranks the factors that are responsible to accelerate the market growth driven by upper hand of CGM over Self monitoring glucose devices, approval for artificial pancreas and many more - Market is forecasted for period of seven years 2013 to 2020 with market revenues for 2 historic years of 20110and 2012 - Identification and analysis of key pockets of investment for CGM manufacturers - Identification of challenges that must be addressed and overcome in the CGM market to achieve fiscal success throughout the market - Analysis of regulatory framework that regulates introduction of new CGM and puts light on reimbursement scenario - The report identifies and profiles key market participants that would drive innovation in the CGM market Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Continuous Glucose Monitors Market Overview Chapter 4 Continuous Glucose Monitoring Systems Market - By Devices Chapter 5 Continuous Glucose Monitoring System Market - By Application Chapter 6 Continuous Glucose Monitoring System Market - By Age Chapter 7 Cgm Systems Market By Geography Chapter 8 Company Profiles - Animas Corporation - Dexcom Inc. - Insulet Corporation - Medtronic Inc. - Novo Nordisk - Roche - Spring Health Solution Ltd - Ypsomed AG For more information visit http://www.researchandmarkets.com/research/k2xw8h/continuous
Upgrade Alert for Insulet (PODD)
Comtex SmarTrend(R) - Fri May 09, 7:01AM CDT
Insulet (NASDAQ
ODD) was upgraded from Sell to Hold at Feltl today. The stock closed yesterday at $31.69 on volume of 2.1 million shares, above average daily volume of 689,000. In the past 52 weeks, shares of Insulet have traded between a low of $24.70 and a high of $51.31 and closed yesterday at $31.69, which is 28% above that low price. The 200-day and 50-day moving averages have moved 0.16% higher and 1.79% lower over the past week, respectively. Insulet Down 32.5% Since SmarTrend Downtrend Call (PODD)
Comtex SmarTrend(R) - Thu May 08, 5:05PM CDT
SmarTrend identified a Downtrend for Insulet (NASDAQ
ODD) on March 31st, 2014 at $46.97. In approximately 1 month, Insulet has returned 32.53% as of today's recent price of $31.69. Insulet Reports First Quarter 2014 Results
Marketwire - Wed May 07, 3:16PM CDT
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced financial results for the first quarter ended March 31, 2014.
Insulet Corporation to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
Marketwire - Wed May 07, 5:02AM CDT
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, today announced the Company will participate in the Bank of America Merrill Lynch 2014 Health Care Conference taking place at the Wynn Hotel in Las Vegas, Nevada. Management is scheduled to present an overview of the Company on Thursday, May 15, 2014 at 10:40 a.m. PT (1:40 p.m. ET).
19.3% Return Seen to Date on SmarTrend Insulet Call (PODD)
Comtex SmarTrend(R) - Thu May 01, 11:13AM CDT
SmarTrend identified a Downtrend for Insulet (NASDAQ
ODD) on March 31st, 2014 at $46.97. In approximately 1 month, Insulet has returned 19.31% as of today's recent price of $37.90. Insulet Corporation to Report First Quarter 2014 Financial Results on May 7, 2014
Marketwire - Tue Apr 29, 3:15PM CDT
Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, announced plans to release its financial results for the first quarter of 2014 on May 7, 2014 after the close of the financial markets.
Xeris Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 2 Clinical Trial of its Investigational Soluble Glucagon Formulation for Pumps
GlobeNewswire - Thu Apr 24, 11:20AM CDT
Xeris Pharmaceuticals, Inc. ("Xeris"
, a clinical stage, specialty biopharmaceutical company developing novel, non-aqueous formulations of injectable drugs, announced today the dosing of the first subject in a Phase 2 clinical study of the company's stable liquid glucagon in an Insulet Corporation OmniPod infusion pump in patients with type 1 diabetes under a new US Investigational New Drug (IND) application. Xeris' G-Pump(TM) (glucagon infusion), a room-temperature stable glucagon solution, is a potentially effective and convenient treatment for hypoglycemia or low blood sugar. Currently, no commercial glucagon product is approved for use in any infusion pump. Glucagon is only approved and available in emergency kits (GEKs) marketed by Eli Lilly and Company and Novo Nordisk for the treatment of severe hypoglycemia. However, with these products, glucagon is available only as a dry powder in a sealed vial that must be reconstituted using a water-filled syringe in a multi-step process prior to injection. Xeris' glucagon formulation is a stable, ready-to-inject liquid which can be packaged and delivered with a variety of devices including auto-injectors, multi-dose pens and pumps. Downtrend Call Working As Insulet Stock Falls 12.3% (PODD)
Comtex SmarTrend(R) - Thu Apr 24, 10:05AM CDT
SmarTrend identified a Downtrend for Insulet (NASDAQ
ODD) on March 31st, 2014 at $46.97. In approximately 3 weeks, Insulet has returned 12.31% as of today's recent price of $41.19. Equities to Watch in the Health Care Sector -- Research on Boston Scientific, Abbott Laboratories, Medtronic, and Insulet
PR Newswire - Thu Apr 24, 7:33AM CDT
The trading session on Wednesday, April 23, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,501.65, down 0.08% and the NASDAQ Composite closed at 4,126.97, down 0.83%. The S&P 500 finished the session 0.22% lower at 1,875.39. During the session, Telecommunication Services, Information Technology, and Health Care sectors exerted a drag, while some positive momentum was observed in the Energy, Industrials, and Financials sectors. The S&P 500 Health Care Sector Index edged 0.48% lower to finish the day at 670.12, while it has gained 1.59% in the last three months. Investor-Edge has initiated coverage on the following equities: Boston Scientific Corp. (NYSE: BSX), Abbott Laboratories (NYSE: ABT), Medtronic Inc. (NYSE: MDT) and Insulet Corp. (NASDAQ: PODD). Free technical research on BSX, ABT, MDT and PODD can be downloaded upon signing up at:
Shares of PODD Down 9.4% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Apr 16, 9:32AM CDT
SmarTrend identified a Downtrend for Insulet (NASDAQ
ODD) on March 31st, 2014 at $46.97. In approximately 2 weeks, Insulet has returned 9.41% as of today's recent price of $42.55. The US Diabetic Devices Industry Outlook to 2018 - Growth to be Led by Next Generation Technology
M2 - Mon Apr 07, 11:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3z9ktc/the_us_diabetic) has announced the addition of the "The US Diabetic Devices Industry Outlook to 2018 - Growth to be Led by Next Generation Technology" report to their offering. The report titled The US Diabetic Devices Industry Outlook to 2018- Growth to be Led by Next Generation Technology presents a comprehensive analysis of the industry covering aspects including market size of SMBG devices, CGM systems and Insulin Delivery Devices market by revenue and market segmentation by product categories in SMBG devices and Insulin Delivery Devices market. The report also entails a detailed description on the recent trends and developments in the diabetic care devices market and competitive scenario of major players in the industry along with market share of major companies in SMBG devices and Insulin Delivery devices market. Key Topics Covered: 1. The US Diabetes Care Devices Market Introduction 1.1. What is Diabetes and it's Types? 2. The US Diabetes Care Devices Market Size, 2007-2013 3. The US Diabetes Care Devices Market Segmentation, 2007-2013 3.1. By Blood Sugar Monitoring Devices, CGM Devices and Insulin Delivery Devices, 2010-2013 3.2. The US Self Blood Glucose Monitoring Devices Market Introduction 3.3. The US CGM Systems Market Introduction 3.4. The US Insulin Delivery Devices Market Size and Introduction, 2007-2013 3.5. Cause & Effect Relationship Analysis in the US Diabetic Care Devices Industry 4. Artificial Pancreas - The Ultimate Goal 5. Trends and Developments in the US Diabetic Care Devices Market 6. Prevalence of Diabetes across the US States 7. Patents Scenario in the US Diabetic Therapeutic Market 8. Strategic Partnerships and Acquisitions in the US Diabetic Market 9. The US Diabetic Care Devices Market SWOT Analysis 10. Company Profiles of Major Players in the US Diabetic Care Devices Market 11. The US Diabetic Care Devices Market Future Outlook and Projections, 2014-2018 12. The US Macro Economic Indicators: Current and Projections 12.1. Ageing Population in the US, 2007-2018 12.2. Consumer Healthcare Expenditure, 2007-2018 12.3. Diabetic Population in the US, 2007-2018 13. Appendix Companies Mentioned - Abbot laboratories - Dexcom inc - Insulet Corporation - LifeScan Inc - Medtronics - Novo Nordisk - Roche Diagnostics For more information visit http://www.researchandmarkets.com/research/3z...s_diabetic
Shares of PODD Up 33.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Mar 26, 4:43PM CDT
SmarTrend identified an Uptrend for Insulet (NASDAQ
ODD) on November 29th, 2013 at $36.86. In approximately 4 months, Insulet has returned 33.32% as of today's recent price of $49.14. Sean Busby Becomes First Person With Type 1 Diabetes to Successfully Backcountry Snowboard All Seven Continents
Marketwire - Thu Mar 20, 9:36AM CDT
Riding On Insulin, a nonprofit organization that empowers, activates and connects the global diabetes community through shared experience and action sports, and Insulet (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod(R) Insulin Management System, are proud to announce that professional snowboarder Sean Busby has become the first person with type 1 diabetes (T1D) to successfully backcountry snowboard on each of the seven continents. Sean, an OmniPod ambassador and the founder of Riding On Insulin, began his seven-continent mission in 2008, just four years after he was diagnosed with type 1 diabetes while training for the 2010 Olympics. From Antarctica in 2008 to Africa in 2014, Sean explored remote corners of the globe while proving that T1D can't stop people from reaching the highest peaks in life.
Increased Earnings Estimates Seen for Insulet (PODD): Can It Move Higher? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:31AM CDT
Insulet has decent short-term momentum and is seeing solid activity on the earnings estimate revision front. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Insulet could be a solid choice for investors.
Concise Analysis of the International Insulin Pump Market
M2 - Tue Mar 18, 5:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wwx6kq/insulin_pump) has announced the addition of the "Concise Analysis of the International Insulin Pump Market" report to their offering. Insulin Pumps are gaining strong acceptance in the market as insulin delivery systems especially for type 1 diabetes patients. Insulin pumps are gaining a lot of attraction in United States and European countries. But due to high costs of insulin pumps it has still not able to penetrate successfully in emerging markets. If insulin pump cost declines then its market is expected to grow immensely. Number of insulin pump users is expected to grow with single digit CAGR for the period of 2013 to 2018. For the year 2013 United States is having the highest market share in insulin pump market worldwide. In terms of companies share Medtronic controls a major portion of insulin pump market globally. Insulin pump market is more than 4 Billion for the year 2013. Reimbursement plays an important factor for the growth of insulin pump in any country. 1. Overall Diabetes Population (2007 - 2018) 2. Type 1 Diabetes Population (2007 - 2018) 3. Type 2 Diabetes Population (2007 - 2018) 4. Insulin Pump Users (2007 - 2018) 5. Insulin Pump Market (2007 - 2018) 6. Reimbursement Policies of all the 16 Countries Key Topics Covered: 1. Executive Summary 2. Worldwide - Insulin Pump Users & Forecast 3. Worldwide - Insulin Pump Market & Forecast 4. Worldwide - Insulin Pump Market Share & Forecast 5. United States - Insulin Pump Analysis 6. Canada - Insulin Pump Analysis 7. Japan - Insulin Pump Analysis 8. Germany - Insulin Pump Analysis 9. Norway - Insulin Pump Analysis 10. Australia - Insulin Pump Analysis 11. Italy - Insulin Pump Analysis 12. Spain - Insulin Pump Analysis 13. France - Insulin Pump Analysis 14. Netherlands - Insulin Pump Analysis 15. Switzerland - Insulin Pump Analysis 16. Sweden - Insulin Pump Analysis 17. Israel - Insulin Pump Analysis 18. United Kingdom - Insulin Pump Analysis 19. Denmark - Insulin Pump Analysis 20. Finland - Insulin Pump Analysis 21. Worldwide Insulin Pump - Key Players Analysis 22. Growth Drivers 23. Challenges Companies Mentioned: - Animas Corporation (Acquired by Johnson & Johnson) - Insulet Corporation - Medtronic - Roche For more information visit http://www.researchandmarkets.com/research/ww...sulin_pump
Uptrend Call Working As Insulet Stock Rises 30.5% (PODD)
Comtex SmarTrend(R) - Wed Mar 12, 9:36AM CDT
SmarTrend identified an Uptrend for Insulet (NASDAQ
ODD) on November 29th, 2013 at $36.86. In approximately 3 months, Insulet has returned 30.55% as of today's recent price of $48.12. Upcoming Conferences, Financial Results, New Products, and Awareness Campaigns - Analyst Notes on Align Technology, LabCorp, Insulet, CareFusion, and DexCom
PR Newswire - Tue Mar 11, 8:20AM CDT
Today, Analysts Review released its analysts' notes regarding Align Technology, Inc. (NASDAQ:ALGN), Laboratory Corp. of America Holdings (NYSE:LH), Insulet Corporation (NASDAQ
ODD), CareFusion Corporation (NYSE:CFN), and DexCom, Inc. (NASDAQ XCM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register Earnings Estimates Moving Higher for Insulet (PODD): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 7:47AM CST
Insulet has decent short-term momentum plus a solid activity on the earnings estimate revision front as well
Global Continuous Glucose Monitoring (CGM Systems, Application, Diabetic Type, and Adoption by Age Group) Market to 2020
M2 - Thu Mar 06, 11:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/k2xw8h/continuous) has announced the addition of the "Continuous Glucose Monitoring Market (CGM Systems, Application, Diabetic Type, and Adoption by Age Group) - Current Trends, Size, Share, Industry Analysis, Competitive Intelligence, Growth, Opportunities and Global Forecasts, 2012 - 2020" report to their offering. The global continuous glucose monitors market generated revenue of $194.8 million in 2012 and is expected to reach market size of value $568.5 million by 2020, growing at a CAGR of 14.8% during 2013-2020. This growth is attributed to increase in technological innovations, namely launch of artificial pancreas, convenience offered by CGM over self monitoring glucose devices, and earlier detection of the hypo & hyperglycemic events by CGM. Global CGM market is segmented based on application as home settings, diagnostics and hospitals. Among all the application segments home settings is expected to generate maximum revenue by 2020. North America is the maximum revenue-generating segment across the globe, mainly due to rapid acceptance of innovative technology, well-penetrated reimbursement system when compared with other geographies and rise in patient pool. Asia Pacific is expected to grow at a faster rate due to large patient pool, geographical expansion of market players, increase in income levels and improved living standards of the people. Key market players in this market includes, Medtronics, Dexcom, Animas Corporation, Ypsomed AG, Omnipod and Miraculins, Inc inlcuding others. The major strategy adopted the market players across this geography is Collaborations, Product launches and approvals. Collaborations specifically focus on distribution and commercialization of the devices. KEY BENEFITS - The report ranks the factors that are responsible to accelerate the market growth driven by upper hand of CGM over Self monitoring glucose devices, approval for artificial pancreas and many more - Market is forecasted for period of seven years 2013 to 2020 with market revenues for 2 historic years of 20110and 2012 - Identification and analysis of key pockets of investment for CGM manufacturers - Identification of challenges that must be addressed and overcome in the CGM market to achieve fiscal success throughout the market - Analysis of regulatory framework that regulates introduction of new CGM and puts light on reimbursement scenario - The report identifies and profiles key market participants that would drive innovation in the CGM market Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Continuous Glucose Monitors Market Overview Chapter 4 Continuous Glucose Monitoring Systems Market - By Devices Chapter 5 Continuous Glucose Monitoring System Market - By Application Chapter 6 Continuous Glucose Monitoring System Market - By Age Chapter 7 Cgm Systems Market By Geography Chapter 8 Company Profiles - Animas Corporation - Dexcom Inc. - Insulet Corporation - Medtronic Inc. - Novo Nordisk - Roche - Spring Health Solution Ltd - Ypsomed AG For more information visit http://www.researchandmarkets.com/research/k2xw8h/continuous
